Generic name: MEDROXYPROGESTERONE ACETATE 400mg in 1mL
Dosage form: injection, suspension
Medically reviewed on August 24, 2017.
The suspension is intended for intramuscular administration only, rotating the sites with every injection. As with any intramuscular injection, to avoid an inadvertent subcutaneous injection, body habitus should be assessed prior to each injection to determine if a longer needle is necessary particularly for gluteal intramuscular injection.
Endometrial or Renal Carcinoma
Doses of 400 mg to 1000 mg of DEPO-PROVERA Sterile Aqueous Suspension per week are recommended initially. If improvement is noted within a few weeks or months and the disease appears stabilized, it may be possible to maintain improvement with as little as 400 mg per month. Medroxyprogesterone acetate is not recommended as primary therapy, but as adjunctive and palliative treatment in advanced inoperable cases including those with recurrent or metastatic disease.
Of the 349 subjects in a clinical study of Depo Provera in renal carcinoma, 30 percent were 65 and over, while 5 percent were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
DEPO-PROVERA Sterile Aqueous Suspension should not be used by women with significant liver disease and should be discontinued if jaundice or disturbances of liver function occur [see PRECAUTIONS].
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Depo-Provera (medroxyprogesterone)
- Depo-Provera Side Effects
- During Pregnancy or Breastfeeding
- Drug Interactions
- Compare Alternatives
- Support Group
- Pricing & Coupons
- En Español
- 1343 Reviews
- Generic Availability
- Drug class: contraceptives
- FDA Alerts (1)